Antiviral drug allergy.
Milpied-Homsi B, Moran EM, Phillips EJ.
Immunol Allergy Clin North Am · research-article; review; journal article · DOI 10.1016/j.iac.2014.04.011 PUBLIKATIONSREGISTRET
Gå till forskningen.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för maraviroc. Visa hela publikationsregistret
En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publikationer i urvalet
19 träffarMaraviroc, a CCR5 antagonist, ameliorates the development of hepatic steatosis in a mouse model of non-alcoholic fatty liver disease (NAFLD).
Pérez-Martínez L, Pérez-Matute P, Aguilera-Lizarraga J, Rubio-Mediavilla S, Narro J, Recio E, Ochoa-Callejero L, Oteo JA, Blanco JR.
J Antimicrob Chemother · research support, non-u.s. gov't; journal article · DOI 10.1093/jac/dku071Maraviroc reduces the regulatory T-cell frequency in antiretroviral-naive HIV-infected subjects.
Pozo-Balado MM, Martínez-Bonet M, Rosado I, Ruiz-Mateos E, Méndez-Lagares G, Rodríguez-Méndez MM, Vidal F, Muñoz-Fernández MA, Pacheco YM, Leal M.
J Infect Dis · research support, non-u.s. gov't; journal article · DOI 10.1093/infdis/jiu180Five-year safety evaluation of maraviroc in HIV-1-infected treatment-experienced patients.
Gulick RM, Fatkenheuer G, Burnside R, Hardy WD, Nelson MR, Goodrich J, Mukwaya G, Portsmouth S, Heera JR.
J Acquir Immune Defic Syndr · clinical trial, phase iii; brief-report; research support, non-u.s. gov't; randomized controlled trial; journal article; research support, n.i.h., extramural · DOI 10.1097/qai.0b013e3182a7a97aImmunologic effectiveness of maraviroc- and raltegravir-containing regimens (R+M+) versus raltegravir-based regimens that do not include maraviroc (R+M-).
Antoniou T, Smith G, Su D, Raboud JM, Lee D, Kovacs C, Brunetta J, Fletcher D, Crouzat F, Loutfy M.
J Int Assoc Physicians AIDS Care (Chic) · comparative study; research support, non-u.s. gov't; journal article · DOI 10.1177/1545109711424967Recent progress in small molecule CCR5 antagonists as potential HIV-1 entry inhibitors.
Chen W, Zhan P, De Clercq E, Liu X.
Curr Pharm Des · research support, non-u.s. gov't; review; journal article · DOI 10.2174/138161212798919084Once daily maraviroc 300 mg or 150 mg in combination with ritonavir-boosted darunavir 800/100 mg.
Okoli C, Siccardi M, Thomas-William S, Dufty N, Khonyongwa K, Ainsworth J, Watson J, Cook R, Gandhi K, Hickinbottom G, Owen A, Taylor S.
J Antimicrob Chemother · research support, non-u.s. gov't; journal article · DOI 10.1093/jac/dkr493Drug safety evaluation of maraviroc for the treatment of HIV infection.
Wasmuth JC, Rockstroh JK, Hardy WD.
Expert Opin Drug Saf · review; journal article · DOI 10.1517/14740338.2012.640670Modulatory effects of the CCR5 antagonist maraviroc on microglial pro-inflammatory activation elicited by gp120.
Lisi L, Tramutola A, De Luca A, Navarra P, Dello Russo C.
J Neurochem · journal article · DOI 10.1111/j.1471-4159.2011.07549.xHIV-1 clinical isolates resistant to CCR5 antagonists exhibit delayed entry kinetics that are corrected in the presence of drug.
Putcharoen O, Lee SH, Henrich TJ, Hu Z, Vanichanan J, Coakley E, Greaves W, Gulick RM, Kuritzkes DR, Tsibris AM.
J Virol · clinical trial; research-article; journal article; research support, n.i.h., extramural · DOI 10.1128/jvi.06421-11In vitro phenotypic susceptibility of HIV-2 clinical isolates to CCR5 inhibitors.
Visseaux B, Charpentier C, Hurtado-Nedelec M, Storto A, Antoine R, Peytavin G, Damond F, Matheron S, Brun-Vézinet F, Descamps D, French ANRS HIV-2 Cohort (ANRS CO 05 VIH-2).
Antimicrob Agents Chemother · research support, non-u.s. gov't; research-article; journal article · DOI 10.1128/aac.05313-11CCR5 antagonism in HIV infection: current concepts and future opportunities.
Wilkin TJ, Gulick RM.
Annu Rev Med · research-article; review; journal article · DOI 10.1146/annurev-med-052010-145454CNS effects of a CCR5 inhibitor in HIV-infected subjects: a pharmacokinetic and cerebral metabolite study.
Garvey L, Nelson M, Latch N, Erlwein OW, Allsop JM, Mitchell A, Kaye S, Watson V, Back D, Taylor-Robinson SD, Winston A.
J Antimicrob Chemother · research support, non-u.s. gov't; clinical trial, phase i; journal article · DOI 10.1093/jac/dkr427Synergistic inhibition of R5 HIV-1 by maraviroc and CCR5 antibody HGS004 in primary cells: implications for treatment and prevention.
Latinovic O, Le N, Reitz M, Pal R, DeVico A, Foulke JS, Redfield RR, Heredia A.
AIDS · research-article; journal article; research support, n.i.h., extramural · DOI 10.1097/qad.0b013e3283471edbLessons from maraviroc clinical trials.
Troia-Cancio P, Asmuth DM.
Expert Rev Anti Infect Ther · comment; journal article · DOI 10.1586/eri.11.52Pharmacokinetic interactions of maraviroc with darunavir-ritonavir, etravirine, and etravirine-darunavir-ritonavir in healthy volunteers: results of two drug interaction trials.
Kakuda TN, Abel S, Davis J, Hamlin J, Schöller-Gyüre M, Mack R, Ndongo N, Petit W, Ridgway C, Sekar V, Tweedy S, Hoetelmans RM.
Antimicrob Agents Chemother · research support, non-u.s. gov't; research-article; clinical trial, phase i; randomized controlled trial; journal article · DOI 10.1128/aac.01046-10Maraviroc is able to inhibit dual-R5 viruses in a dual/mixed HIV-1-infected patient.
Symons J, Symons J, van Lelyveld SF, Hoepelman AI, van Ham PM, de Jong D, Wensing AM, Nijhuis M.
J Antimicrob Chemother · research support, non-u.s. gov't; journal article; case reports · DOI 10.1093/jac/dkq535Clinical utility of maraviroc.
Parra J, Portilla J, Pulido F, Sánchez-de la Rosa R, Alonso-Villaverde C, Berenguer J, Blanco JL, Domingo P, Dronda F, Galera C, Gutiérrez F, Kindelán JM, Knobel H, Leal M, López-Aldeguer J, Mariño A, Miralles C, Moltó J, Ortega E, Oteo JA.
Clin Drug Investig · research support, non-u.s. gov't; review; journal article · DOI 10.2165/11590700-000000000-00000Discordance rates between Trofile test and short-term virological response to maraviroc.
Genebat M, Ruiz-Mateos E, González-Serna A, Pulido I, Muñoz-Fernández MÁ, Ferrando-Martínez S, Leal M.
Antiviral Res · research support, non-u.s. gov't; journal article · DOI 10.1016/j.antiviral.2010.11.015